These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 38717250)
1. Temozolomide resistance mechanisms: unveiling the role of translesion DNA polymerase kappa in glioblastoma spheroids in vitro. Ribeiro DL; Latancia MT; de Souza I; Ariwoola AA; Mendes D; Rocha CRR; Lengert AVH; Menck CFM Biosci Rep; 2024 May; 44(5):. PubMed ID: 38717250 [TBL] [Abstract][Full Text] [Related]
2. Human translesion DNA polymerases ι and κ mediate tolerance to temozolomide in MGMT-deficient glioblastoma cells. Latancia MT; Leandro GDS; Bastos AU; Moreno NC; Ariwoola AA; Martins DJ; Ashton NW; Ribeiro VC; Hoch NC; Rocha CRR; Woodgate R; Menck CFM DNA Repair (Amst); 2024 Sep; 141():103715. PubMed ID: 39029375 [TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways. Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459 [TBL] [Abstract][Full Text] [Related]
4. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines. Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465 [TBL] [Abstract][Full Text] [Related]
5. Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma. Tiek DM; Rone JD; Graham GT; Pannkuk EL; Haddad BR; Riggins RB Sci Rep; 2018 May; 8(1):7222. PubMed ID: 29740146 [TBL] [Abstract][Full Text] [Related]
6. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2. Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849 [TBL] [Abstract][Full Text] [Related]
7. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863 [TBL] [Abstract][Full Text] [Related]
8. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
9. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
10. Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT. Duan C; He B; Wang Y; Liu W; Bao W; Yu L; Xin J; Gui H; Lei J; Yang Z; Liu J; Tao W; Qin J; Luo J; Dong Z Sci Rep; 2024 Aug; 14(1):20199. PubMed ID: 39215105 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
12. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency. Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889 [TBL] [Abstract][Full Text] [Related]
13. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. Wang HH; Chang TY; Lin WC; Wei KC; Shin JW Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714 [TBL] [Abstract][Full Text] [Related]
14. Unveiling the Pharmacological Role of Human Deubiquitinating Enzymes in Temozolomide Response of Glioblastoma Cells. Yang C; Li Y; Wu Q; Tang J; Chen M; Zhang B; Li B; Qin Y; Huang G; Zhang Y; Zhi F; Liu K Cell Biochem Biophys; 2024 Sep; 82(3):2183-2193. PubMed ID: 38809352 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. Liang H; Chen Z; Sun L Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274 [TBL] [Abstract][Full Text] [Related]
16. pH as a potential therapeutic target to improve temozolomide antitumor efficacy : A mechanistic modeling study. Stéphanou A; Ballesta A Pharmacol Res Perspect; 2019 Feb; 7(1):e00454. PubMed ID: 30705757 [TBL] [Abstract][Full Text] [Related]
17. Downregulating DNA methyltransferase 3B by suppressing the PI3K/Akt signaling pathway enhances the chemosensitivity of glioblastoma to temozolomide. Kan W; Gao L; Chen J; Chen L; Zhang G; Hao B; He M; Chen X; Wang C Mol Neurobiol; 2024 Sep; 61(9):7066-7074. PubMed ID: 38368287 [TBL] [Abstract][Full Text] [Related]
18. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related]
19. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance. Li Y; Wang X; Xu T; Xu F; Chen T; Li Z; Wang Y; Chen H; Ming J; Cai J; Jiang C; Meng X Cancer Lett; 2024 Aug; 598():217107. PubMed ID: 38992489 [TBL] [Abstract][Full Text] [Related]
20. Muscone restores anoikis sensitivity in TMZ-resistant glioblastoma cells by suppressing TOP2A via the EGFR/Integrin β1/FAK signaling pathway. Zou Y; Xu L; Wang W; Zhu X; Lin J; Li H; Chen J; Xu W; Gao H; Wu X; Yin Z; Wang Q Phytomedicine; 2024 Jul; 129():155714. PubMed ID: 38723526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]